Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection ofp53 gene mutations using cDNA sequencing in human breast tumors
Open Access
- 21 August 1998
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 79 (4) , 376-383
Abstract
The p53mutational status of 226 representative primary breast cancer samples, derived from a population‐based cohort, was analyzed using cDNA‐based sequencing. The results were compared with those obtained with immunohistochemistry (IHC) on microwave‐treated paraffin sections and the p53 specific luminometric immunoassay (LIA) on cytosols, all from the same individuals. Thirty‐seven mutations were found using cDNA sequencing and were categorized into A) missense mutations in the evolutionarily conserved regions; B) missense mutations outside the evolutionarily regions; and C) deletions, insertions and nonsense mutations. Using optimal cut‐off values, LIA detected 15 of 16 missense mutations in category A, in which IHC detected all 16. In category B, 10 of 13 and 7 of 13 mutations were detected, respectively. Some of the samples in category A had a very high p53 protein content when measured with the LIA, the reason for this being discussed. IHC detected 0 of 5 stop codon and 0 of 3 deletions/insertions mutations, while the LIA method detected 2 of 5 stop codon mutations and 1 of 3 deletion/insertion mutations. Compared with cDNA sequencing, protein analyses using optimal cut‐off values resulted in an overall sensitivity and specificity of 64.9% and 89.9%, respectively, for the LIA method. Corresponding values were 72.2% and 92% for IHC. In addition, patients from whom p53 mutations could be detected by cDNA sequencing had a statistically significant (p = 0.0137) shorter survival, which was not readily apparent using the alternative LIA or IHC approaches at optimal cut‐off values. Int. J. Cancer (Pred. Oncol.) 79:376–383, 1998.Keywords
This publication has 24 references indexed in Scilit:
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysisInternational Journal of Cancer, 1996
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNature Medicine, 1995
- TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, Chromosomes and Cancer, 1995
- Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosolsBritish Journal of Cancer, 1995
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 1993
- p53 alterations in all stages of breast cancerJournal of Surgical Oncology, 1991
- Evidence implicating at least two genes on chromosome 17p in breast carcinogenesisThe Lancet, 1990
- Isolation of human‐p53‐specific monoclonal antibodies and their use in the studies of human p53 expressionEuropean Journal of Biochemistry, 1986